Cervical
squamous cell carcinomas are composed histologically of tumour cell islands surrounded by varying amounts of tumour stroma, the amount and composition of which are influenced by local TGF-beta(1). TGF-beta(1) is secreted in an inactive complex with latency-associated
peptide (LAP). Both LAP and the extracellular matrix (ECM)
protein fibronectin are important
ligands for the
integrin receptor alpha v beta 6. While alpha v beta 6 is only weakly expressed by normal epithelia, it is up-regulated in different
carcinomas where it generally reflects a more aggressive phenotype. In
cervical cancer, the expression of alpha v beta 6 has not thus far been investigated. Given the ability of alpha v beta 6 both to activate TGF-beta(1) and to interact with
fibronectin, we studied correlations between the expression of these components and disease parameters in a large cohort of
cervical cancer specimens. We analysed alpha v beta 6 expression using immunohistochemistry in primary cervical
squamous carcinomas of FIGO stage IA to IIB patients and correlated the findings with formerly investigated
fibronectin and TGF-beta(1) expression and clinico-pathological parameters. alpha v beta 6 expression was also examined in cervical intra-epithelial
neoplasia (CIN) and
lymph node metastases. alpha v beta 6 was only weakly expressed in normal epithelium but clearly up-regulated in CIN lesions. In
carcinomas, strong expression of alpha v beta 6 in tumour cells correlated with different clinico-pathological parameters and with worse overall and disease-free survival. Furthermore, alpha v beta 6 expression correlated positively with TGF-beta(1)
mRNA expression as well as with
fibronectin expression. Overexpression of alpha v beta 6 in cervical
squamous carcinomas is an unfavourable prognostic factor. This might reflect an increased capacity of alpha v beta 6-expressing tumour cells to migrate in a
fibronectin-rich ECM and/or to activate TGF-beta(1) at the tumour/stroma interface, both of which processes may contribute to
cervical cancer progression.